Fresenius SE & Co. KGaA Inh.-Akt.(Spons.ADRs) 1/4/o.N.
Sector and Industry
Healthcare, Healthcare Services
Performance (1Y)
15.60%
Market Cap
21.29 Bil.
P/E Ratio
22.71
Dividend Yield
1.41 %
Earnings per Share
0.56 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| UnitedHealth Group Inc. | 254.66 Bil. | 396.73 Bil. | 24.94 | -19.75 % | 0.00 | - |
| Thermo Fisher Scientific Inc. | 185.62 Bil. | 39.50 Bil. | 32.67 | +1.45 % | 0.00 | - |
| Danaher Corp. | 137.79 Bil. | 21.78 Bil. | 45.36 | -11.47 % | 0.00 | - |
| McKesson Corporation | 90.13 Bil. | 348.09 Bil. | 22.55 | +33.83 % | 0.00 | - |
| HCA Healthcare Inc. | 89.28 Bil. | 67.01 Bil. | 16.48 | +12.93 % | 0.00 | - |
| Elevance Health Inc. | 65.88 Bil. | 176.51 Bil. | 13.91 | -9.22 % | 0.00 | - |
| The Cigna Group | 61.74 Bil. | 243.65 Bil. | 12.41 | +66.33 % | 0.00 | - |
| Cencora Inc. | 51.58 Bil. | 291.15 Bil. | 39.26 | +1.16 % | 0.00 | - |
| IDEXX Laboratories Inc. | 45.92 Bil. | 3.81 Bil. | 51.74 | +14.41 % | 0.00 | - |
| Zoetis Inc. | 45.52 Bil. | 8.39 Bil. | 20.89 | +3.10 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 9.5 G | 0 Units |
| PRICE DETERMINATION TIME | 06/16/2026 / 08:55:05 AM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 9.55 | 9.15 |
| PREV. DAY'S PRICE | 9.45 | (06/15) |
| CHANGE DAY BEFORE | +0.05 | 0.53 % |
| 52 WEEK HIGH / LOW | 17.7 (11/03) | 8.45 (06/02) |
Key Figures (in EUR)
| 2027e | 2026e | 2025 | 2024 | 2023 | |
|---|---|---|---|---|---|
| EARNINGS PER SHARE | 0.99 | 0.91 | 0.56 | 0.21 | -0.26 |
| DIVIDENDS PER SHARE | 0.30 | 0.28 | 0.18 | 0.17 | 0.00 |
| DIVIDEND YIELD IN % | - | - | 1.41 % | 2.17 % | 0.00 % |
| DIVIDEND GROWTH IN % | - | - | 3.34 % | - | -100.00 % |
| PRICE - EARNINGS RATIO | 9.54 | 10.37 | 22.71 | 38.40 | - |
| PRICE - BOOK RATIO | - | - | 1.44 | 0.97 | 0.83 |
| PRICE - SALES RATIO | - | - | 1.26 | 0.83 | 0.72 |
| PRICE - CASH FLOW RATIO | - | - | 10.65 | 7.07 | 3.54 |
Master Data
| WKN | A1XCZQ |
| ISIN | US35804M1053 |
| SYMBOL | FREA |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | FRESENIUS SE+CO. ADR 1/4 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | US Dollar |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Healthcare Services |
| NUMBER OF SHARES | 2.25 Bil. |
| MARKET CAPITALISATION | 21.29 Bil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 1.10 % | -5.64 % | -19.30 % | -20.69 % | -15.60 % | 46.03 % | -17.86 % | -21.37 % |
| HIGH | 9.45 | 10.10 | 11.60 | 13.10 | 17.70 | 17.70 | 17.70 | 13.10 |
| LOW | 8.80 | 8.45 | 8.45 | 8.45 | 8.45 | 5.90 | 4.88 | 8.45 |
Dividend
per share
Company profile
Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. It operates through the following segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed. The Fresenius Medical Care segment caters to individuals with renal diseases. The Fresenius Kabi segment specializes in lifesaving medicines and technologies. The Fresenius Helios offers expertise in inpatient and outpatient care as well as in telemedicine. The Fresenius Vamed segment manages projects and services for hospitals and other healthcare facilities. The company was founded by Eduard Fresenius on October 1, 1912 and is headquartered in Bad Homburg, Germany.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
(in 50 days)
08/05/26Q2 2026 Earnings Release
(in 50 days)
08/05/26Q2 2026 Earnings Release
(in 141 days)
11/04/26Q3 2026 Earnings Call
(in 141 days)
11/04/26Q3 2026 Earnings Release
(in 252 days)
02/23/27Q4 2026 Earnings Release